Influenza
By Hera Rizwan India reported its first two deaths due to the influenza virus H3N2, on March 10. From January 2 to March 5, 451 cases of H3N2 infection have been reported across the country, according to data shared by the Union health ministry. India witnessed a spike in influenza cases in the past few weeks, with people on social media claiming that H3N2 was spreading like Covid. Some users claimed that H3N2 was spreading like "wild fire". "India every year witnesses two peaks of seasonal influenza: one from Jan to March and the other in the post-monsoon season. The cases arising from season...
BOOM Live
By Hera Rizwan Of late, India is seeing increased cases of influenza which includes symptoms such as cough, cold, fever, and body ache. According to the experts, this year the symptoms are prolonged and are contributing to higher hospitalization rates, than before. A low rate of vaccination and increased pollution are the possible reasons behind the trend, experts said. "Although it is common to have such symptoms during this time of the year, when we are transitioning from one season to another, but we are seeing increased instances and prolonged symptoms this year. We can attribute this to I...
BOOM Live
Paris (AFP) - Experts have warned that the recent detection of bird flu in mammals including foxes, otters, minks, seals and even grizzly bears is concerning but emphasised that the virus would have to significantly mutate to spread between humans. Since late 2021, Europe has been gripped by its worst-ever outbreak of bird flu, with North and South America also experiencing severe outbreaks. This has led to the culling of tens of millions of domestic poultry worldwide, many with the H5N1 strain. The global outbreak is also responsible for the deaths of tens of thousands of wild birds. Tom Peac...
AFP
Washington (AFP) - US pharmaceutical company Pfizer said Monday it had begun a clinical trial to test an influenza vaccine designed with the same mRNA technology behind its successful Covid-19 shot. The idea is to improve on the current generation of flu vaccines that have an efficacy of 40-60 percent against a disease that can cause up to 650,000 deaths a year. "The Covid-19 pandemic allowed us to deliver on the immense scientific opportunity of mRNA," Kathrin Jansen, head of vaccine research at Pfizer, said in a statement. "Influenza remains an area where we see a need for vaccines which cou...
AFP
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら